AXA Q1 Revenues Gains 2%

AXA (AXAHY.PK) Thursday reported its first-quarter total gross revenues of 31.3 billion euros, up 2% from 30.7 billion euros last year. On comparable basis, revenues rose 1% year-over-year.

Property & Casualty segment revenues gained 3% to 18.0 billion euros, while Health segment revenues gained 4% to 4.2 billion euros. Life & Savings slipped 2% to 8.4 billion euros, while Asset Management gained 9% to 0.4 billion euros.

"AXA performed well in the first quarter of 2022, delivering high-quality revenue growth", said Alban de Mailly Nesle, Chief Financial Officer of AXA. "We continue to see strong performance in our technical and fee-based businesses across the Group."

"Our mix is excellent, with Health revenues growing by 6%, Unit-Linked by 5% and P&C Commercial lines Insurance by 4%, with continued favorable pricing momentum across geographies and notably at AXA XL."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT